Shinji Uchida

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study
    Shinji Uchida
    Clinical Development Institute, Banyu Pharmaceutical Co, Ltd, 5 1 Nihombashi kabutocho, Chuo Ku, Tokyo 103 0026, Japan
    J Bone Miner Metab 23:382-8. 2005
  2. ncbi [Pharmacological and clinical profile of once weekly alendronate for the treatment of osteoporosis (Fosamac 35 mg/Bonalon 35 mg)]
    Shinji Uchida
    Nippon Yakurigaku Zasshi 130:305-12. 2007

Detail Information

Publications2

  1. ncbi Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study
    Shinji Uchida
    Clinical Development Institute, Banyu Pharmaceutical Co, Ltd, 5 1 Nihombashi kabutocho, Chuo Ku, Tokyo 103 0026, Japan
    J Bone Miner Metab 23:382-8. 2005
    ..Taken together, we conclude that the efficacy and safety of the ALN 35-mg once-weekly regimen are therapeutically equivalent to those of the ALN 5-mg once-daily regimen...
  2. ncbi [Pharmacological and clinical profile of once weekly alendronate for the treatment of osteoporosis (Fosamac 35 mg/Bonalon 35 mg)]
    Shinji Uchida
    Nippon Yakurigaku Zasshi 130:305-12. 2007